However, other studies have failed to find a protective effect of dietary folate or folate supplements against endometrial cancer, 25 ' 26 vulvar cancer, 27 lung cancer, 28 cervical dysplasia, 29 " 32 invasive cervical cancer, 33 " 35 oesophageal and oral cancer, 36 " 38 and colon cancer.
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In addition, adequate concentrations of serum, plasma, or red blood cell folate may protect against cervical dysplasia, 3 ' 40 cervical cancer, 41 oral leucoplacias, 42 colon dysplasia, 43 colon cancer, 43 colon adenomas, 44 cytological abnormalities of oesophageal cells, 45 oesophageal cancer, 36 ' 38 coronary heart disease, 16 ' 46 ' 47 (-afQ^j ar tery stenosis, 4 * stroke, 49 and peripheral artery disease. 50 However, other studies have failed to find lower serum, plasma, or red blood cell folate concentrations among persons with cervical cancer, 40 colorectal cancer, 23 and cardiovascular disease. 50 " 57 A better understanding of folate's role in humans has provided hypotheses about how folate could play a role in the prevention of some chronic diseases. Folate plays an important role in the transfer of methyl and formyl groups to organic compounds. Observations have suggested that deficient methylation of DNA may play a role in carcinogenesis. It is speculated that folate's importance in the transfer of methyl groups may account for its purported beneficial effects against cancer. 13 Folate's potential role in preventing coronary heart disease is largely indirect by helping to determine homocysteine concentrations. After adjustment for plasma homocysteine concentrations, the magnitude of the measures of association in two of these studies was greatly reduced. 46 ' To examine whether serum folate concentrations affects future occurrences of mortality and chronic disease incidence, we analysed data from a nationally representative cohort of US adults from the National Health and Nutrition Examination Survey I (NHANES I) Epidemiologic Follow-up Study. Specifically, we examined whether serum folate concentrations were predictive of all-cause mortality, major circulatory disease mortality or incidence, and cancer mortality or incidence.
Methods
Between 1971 and 1975, 18 836 people aged 12-74 participated in NHANES I. Of these participants, the 14 407 who were 3=25 years at the baseline examination were subsequently followed up. The methods of the original NHANES I survey and the NHANES I Epidemiologic Follow-up Study have been presented in detail elsewhere. 58 " 62 Cohort members were followed through 1992. Serum folate determinations were limited to the 3059 participants in one of the nationally representative subsamples of NHANES I. Serum folate was measured with a microbiological method with a coefficient of variation of 10-20%. 63 Four waves of follow-up data collection were undertaken in 1982-1984, 1986, 1987, and 1992 . The vital status of study participants was determined during each of these periods. Death certificates were obtained for deceased participants. Deaths were classified as being due to diseases of the circulatory system if the underlying code listed one of the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM), rubrics 390-^158 and from cancer if the underlying code listed one of the ICD-9-CM, rubrics 140-208 except 173 (other malignant neoplasm of skin). During the follow-up interviews, study participants or proxies for diseased participants or those incapable of participating in the interview were asked about hospitalizations. Subsequently, hospitals were contacted and hospital discharge sheets were abstracted.
Incidence of diseases of the circulatory system was defined as either a death based on the underlying code or a hospitalization with the ICD-9-CM codes of 390-458 listed among any of the 10 possible diagnoses. Incidence of cancer was defined as either a death based on the underlying code or a hospitalization with the ICD-9-CM codes of 140-208 but not 173 listed among any of the 10 possible diagnoses. We excluded from the analyses for diseases of the circulatory system participants who reported at baseline that they had had a previous heart attack or stroke. We excluded from the analyses for cancer participants who reported at baseline that they had had cancer.
For all-cause mortality and for circulatory disease, the potential confounders we included in the analysis were age, sex, race, education, cigarette smoking, systolic blood pressure, use of anti-hypertensive medication, serum cholesterol, body mass index, recreational and non-recreational physical activity, selfreported diabetes, and alcohol consumption. For cancer, the potential confounders we included in the analysis were age, sex, race, education, cigarette smoking, physical activity and alcohol consumption. For cigarette smoking, we used a variable that was constructed in part from responses obtained during the baseline interview and in part from the first follow-up interview from 1982 through 1984. The validity of this approach has been demonstrated. 64 -65 Using the two questions 'Have you smoked at least 100 cigarettes during your entire life?' and 'Do you smoke cigarettes now?', three categories of smoking were constructed: current smokers, former smokers, and never having smoked. Because no dietary data were collected for our analytic sample, we were unable to adjust for potential dietary confounders.
We adjusted mortality rates (all-cause and cause-specific) for age and sex by the direct method to the 1980 US residential population using three age groups. We performed proportional hazards regression analyses with the software SUDAAN which accounts for the complex sampling design of the study. 66 Proportionality assumptions were checked with the SAS procedure Proc PHREG by creating time-dependent covariates for the independent variables. We also conducted lagged analyses whereby we excluded individuals who died within periods of up to 5 years from entry into the study.
Results
The number of participants available for each analysis and the number of health events are shown in Table 1 . Mean serum folate concentrations for variables included in this analysis are shown in Table 2 . Women had higher folate concentrations than men, current smokers had lower folate concentrations than former or never smokers, participants with a cholesterol concentration <200 mg/dl had lower folate concentrations than participants with a cholesterol concentration of 200-239 mg/dl, overweight participants had lower folate concentrations than participants with normal body mass index, and people taking vitamin supplements had higher folate concentrations than those who did not. Because the associations between serum folate concentrations and disease endpoints were similar for men and women, we present only data for the combined group of study participants. We examined crude and age-adjusted correlation coefficients between serum folate and continuous variables. The largest correlation (r = 0.15) was found between age and serum folate. Age-and sex-adjusted mean folate concentrations for those who subsequently were diagnosed with or died from various causes and those who did not are shown in Table 3 . No significant mortality differences were observed. Participants who later experienced incident circulatory disease had lower mean concentrations of serum folate than did those who remained free of circulatory disease. Age-and sex-adjusted mean serum folate concentrations were 8.3 nmol/1 for 21 participants who died of gastrointestinal cancer (ICD-9-CM 150-154), 9.2 nmol/1 for 13 participants who died of colon cancer (ICD-9-CM 153), and 9.5 nmol/1 for 43 patients with a respiratory cancer (ICD-9-CM 162). Age-adjusted means of serum folate concentrations were 7.9 nmol/1 for 11 women who died of breast cancer (ICD-9-CM 174) compared with 8.5 nmol/1 for women who did not die of cancer and 9.5 nmol/1 for 15 men who died of prostate cancer (ICD-9-CM 199) compared with 8.5 nmol/1 for men who did not die of cancer. None of the differences were statistically significant (P > 0.10). For participants who either died of or were hospitalized for a cancer, the age-and sex-adjusted mean serum folate concentrations were 7.3 nmol/1 for 48 participants who had gastrointestinal cancer, 7.5 nmol/1 for 36 participants who had colon cancer, and 6.7 nmol/1 for 43 patients with a respiratory cancer. Age-adjusted means of serum folate concentrations were 7.3 nmol/1 for 47 women with breast cancer compared with 8.5 nmol/1 for women who did not have cancer and 7.7 nmol/1 for 42 men who died of prostate cancer (ICD-9-CM 199) compared with 7.3 nmol/1 for men who did have cancer. None of the differences were statistically significant (P>0.10).
Mortality and incidence rates are presented in Table 4 . The proportional hazards analyses which included only participants with complete data failed to support any significant relationship between serum folate concentrations and any of the endpoints (Table 4) . We also repeated the cancer mortality analyses by excluding malignant neoplasms of lymphatic and haematopoietic tissue (ICD-9-CM 200-208) and found results similar to those for all cancers.
Although we failed to find a significant relationship between serum folate and all-cause mortality and circulatory disease, plots of the log relative hazard and serum folate concentration suggested a J-shaped relationship between the risk of disease and serum folate concentration with the lowest risk occurring around serum folate concentrations of 18-23 nmol/1. In a post hoc analysis, the hazard ratios were 1.26 (95% CI : 1.01-1.57) for deaths from any cause and 1.41 (95% CI : 0.97-2.06) for deaths from circulatory disease for participants in the lowest quintile of serum folate concentration compared with those in other four quintiles. Eliminating deaths occurring within periods ranging from 1 to 5 years after entry into the study >23.6 nmol/1. mass index, self-reported did not change the magnitude of the hazard ratios appredably. In no instance did we observe a graded dose-response relationship. We found no interaction between age, sex, race, education, or smoking status and serum folate concentration for mortality from and incidence of the various health events. However, the interaction term between serum folate, modelled as a continuous variable, and diabetes status was a significant predictor of all-cause and circulatory disease mortality. For people without diabetes, the hazard ratios were 1.00 (95% CI : 1.00-1.01) and 1.00 (95% CI : 0.99-1.01) for all-cause and circulatory disease mortality, respectively, and for those with diabetes, they were 1.01 (95% CI : 1.00-1.03) and 1.04 (95% CI : 1.01-1.07), respectively.
Discussion
In this nationally representative sample that was followed for about 14 years, low serum folate (<9.3 nmol/1) was associated with small increases in all-cause mortality and cardiovascular disease mortality but not cancer mortality. However, the size of the hazard ratios was small and only for the post-hoc analysis for all-cause mortality did the 95% CI exclude unity. Because the sample size for site-specific cancers was small, we were unable to examine whether serum folate may have had a protective effect on the incidence of those cancers for which previous research supports a possible relationship.
Several limitations may affect the findings of our study. It is possible that our findings may be due to some other unmeasured confounding factor among those with low serum folate concentrations. In addition, folate may be protective for particular conditions that form only a small part of total mortality or the broad groupings of disease we used in this analysis. Thus the effect of folate may have been diluted by broad disease groupings. Measuring serum folate concentrations may not be the best indicator of folate status in individuals. Body stores of folate can be measured in several ways: serum or plasma folate concentrations represent shorter term, whereas red blood cell folate represents intermediate stores. Liver biopsies are perhaps the best measurement of body stores of folate. Potischman concluded that the concentration of red blood cell folate was a better predictor of cervical dysplasia than were either serum folate concentration or dietary intake. 67 We estimate that we had power of ^80% to detect hazard ratios on the order of 1.7 comparing the lowest with the highest quintile of serum folate for all-cause mortality, coronary heart disease mortality and incidence, and all cancer incidence. However, it was impossible for us to conduct analyses with sufficient power for particular categories of cancer. Because some misclassiDcation of exposure is likely, due both to true within person variability and to laboratory assessment variability, actual power may have been lower. Given our findings, we also performed post hoc confidence limit analyses that showed likelihood estimates of less than 5% for finding true hazard ratios of 3=2.0.
Recently, a study of elderly Italians suggested that dietary intake of folate determined from a 24-hour recall was an independent predictor of mortality over a 6-year period. 1 Several studies have suggested that plasma folate concentrations are associated with coronary artery disease and carotid artery stenosis after adjustment for traditional risk factors. 16 '
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However, additional adjustment for homocysteine concentrations usually results in substantial attenuation of these associations. These observations are perhaps not surprising, since folate determines homocysteine concentrations in part. In our study, we noted a non-significant 41% increase in mortality from circulatory diseases for participants in the lowest quintile of serum folate concentration.
In conclusion, we found low serum folate to be weakly associated with an increased risk for mortality from all causes and diseases of the circulatory system but not cancer. Additional research to better define the specificity of the protective health effect of folate is dearly needed. Nevertheless, foods rich in folate such as dark green vegetables, orange juice, and whole grains, have been found to be assodated with reduced risk of cancer and coronary heart disease and should, therefore, be part of everyone's diet.
